Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | NQO2 | P16083 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | XDH | P47989 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15054527 | 0.83 | HTR6 (0.50) | HTR6ALDH1A1CYP3A4PTGS2PTGS1 | |
| SCHEMBL1172197 | 0.82 | L3MBTL1 (0.46) | HTR6ALDH1A1CYP3A4SMN1; SMN2PTGS2 | |
| SCHEMBL2651077 | 0.82 | G6PD (0.43) | HTR6ALDH1A1CYP3A4PTGS2TDP1 | |
| SCHEMBL1606727 | 0.82 | HTR6 (0.49) | HTR6ALDH1A1CYP3A4CYP19A1NQO2 | |
| SCHEMBL31738331 | 0.81 | HTR6 (0.45) | HTR6ALDH1A1CYP3A4CYP19A1NQO2 | |
| SCHEMBL2436557 | 0.81 | LOX (0.51) | HTR6ALDH1A1CYP3A4SMN1; SMN2PKM | |
| SCHEMBL12325146 | 0.80 | HTR6 (0.47) | HTR6ALDH1A1CYP3A4CYP19A1NQO2 | |
| SCHEMBL14633653 | 0.80 | LOX (0.37) | HTR6ALDH1A1SMN1; SMN2 | |
| SCHEMBL30365875 | 0.79 | ALDH1A1 (0.65) | HTR6ALDH1A1CYP3A4CYP19A1NQO2 | |
| SCHEMBL17263616 | 0.79 | RAPGEF4 (0.44) | ALDH1A1SMN1; SMN2XDHPKMPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113045476-B | Monosubstituted or disubstituted indole derivatives as dengue virus replication inhibitors | 杨森制药公司 | 2024-07-16 | — | — | CN | claimed |
| CN-117616010-A | Process for preparing (S) -2- (4-chloro-2-methoxyphenyl) -2- ((3-methoxy-5- (methylsulfonyl) phenyl) amino) -1- (1H-indol-3-yl) ketene derivatives | 杨森制药公司 | 2024-02-27 | — | — | CN | claimed |
| CN-111303000-B | Monosubstituted or disubstituted indole derivatives as dengue virus replication inhibitors | 杨森制药公司 | 2023-11-28 | — | — | CN | claimed |
| EP-3896072-B1 | MONO- OR DI-SUBSTITUTED INDOLE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | JANSSEN PHARMACEUTICALS INC (US) | 2022-11-16 | — | — | EP | claimed |
| EP-3350162-B1 | MONO- OR DI-SUBSTITUTED INDOLE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | JANSSEN PHARMACEUTICALS INC (US) | 2021-07-14 | — | — | EP | claimed |
| EP-4363403-B1 | PROCESSES FOR THE PREPARATION OF (S)-2-(4-CHLORO-2-METHOXYPHENYL)-2-((3-METHOXY-5-(METHYLSULFONYL)PHENYL)AMINO)-1-(1H-INDOL-3-YL)ETHENONE DERIVATIVES | UNIV LEUVEN KATH (BE) | 2026-05-27 | — | — | EP | disclosed |
| EP-4240331-B1 | SOLID FORMULATION | UNIV LEUVEN KATH (BE) | 2026-04-29 | — | — | EP | disclosed |
| US-20250281457-A1 | TREATMENT OR PREVENTION OF DENGUE VIRAL INFECTION | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-09-11 | — | — | US | disclosed |
| US-20250230127-A1 | MONO- OR DI-SUBSTITUTED INDOLE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | JANSSEN PHARMACEUTICALS INC (US) | 2025-07-17 | — | — | US | disclosed |
| US-20250177391-A1 | INHIBITORS OF DDR1 AND DDR2 FOR THE TREATMENT OF ARTHRITIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2025-06-05 | — | — | US | disclosed |
| EP-4522163-A1 | TREATMENT OR PREVENTION OF DENGUE VIRAL INFECTION | Janssen Pharmaceuticals, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-4482825-A2 | INHIBITORS OF DDR1 AND DDR2 FOR THE TREATMENT OF ARTHRITIS | President and Fellows of Harvard College (US) | 2025-01-01 | — | — | EP | disclosed |
| WO-2010038081-A2 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | WO | disclosed |
| WO-2010038081-A2 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | WO | disclosed |
| EP-2114945-A1 | PTERIDINONE DERIVATIVES AS PI3-KINASES INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2009-11-11 | — | — | EP | disclosed |
| WO-2009109483-A1 | LEUKOTRIENE B4 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-11 | — | — | WO | disclosed |
| US-20090227603-A1 | LEUKOTRIENE B4 INHIBITORS | DOMINIQUE ROMYR | 2009-09-10 | — | — | US | disclosed |
| US-20090227603-A1 | LEUKOTRIENE B4 INHIBITORS | DOMINIQUE ROMYR | 2009-09-10 | — | — | US | disclosed |
| WO-2008092831-A1 | PTERIDINONE DERIVATIVES AS PI3-KINASES INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-08-07 | — | — | WO | disclosed |
| EP-1953163-A1 | Pteridinone derivatives as PI3-kinases inhibitors | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2008-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227603-A1 | LEUKOTRIENE B4 INHIBITORS | LTB4R2, LTB4R, LTC4S | HTR6 2030/4885ALDH1A1 685/4885CYP3A4 402/4885 |
| US-20250177391-A1 | INHIBITORS OF DDR1 AND DDR2 FOR THE TREATMENT OF ARTHRITIS | DDR2, DDR1, DDRGK1 | HTR6 3335/4885ALDH1A1 2720/4885CYP3A4 4399/4885 |
| US-20250281457-A1 | TREATMENT OR PREVENTION OF DENGUE VIRAL INFECTION | F3, FOXO3, FOXO1 | HTR6 2712/4885ALDH1A1 1363/4885CYP3A4 76/4885 |
| US-20250230127-A1 | MONO- OR DI-SUBSTITUTED INDOLE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | IDO1, IDO2, IRF3 | HTR6 321/4885ALDH1A1 2351/4885CYP3A4 909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.